| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1019688209 |
| P356 | DOI | 10.1186/BCR2748 |
| P932 | PMC publication ID | 3005739 |
| P698 | PubMed publication ID | 21172081 |
| P5875 | ResearchGate publication ID | 49696584 |
| P50 | author | Adrian Harris | Q37374768 |
| P2093 | author name string | Simon Lord | |
| P2860 | cites work | Hypoxia Response Elements in the Aldolase A, Enolase 1, and Lactate Dehydrogenase A Gene Promoters Contain Essential Binding Sites for Hypoxia-inducible Factor 1 | Q63565692 |
| Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice | Q73587094 | ||
| Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients | Q81126612 | ||
| Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts | Q81388927 | ||
| Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. | Q22255481 | ||
| Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels | Q24299513 | ||
| Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis | Q24608039 | ||
| Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases | Q28139317 | ||
| The Expression and Distribution of the Hypoxia-Inducible Factors HIF-1α and HIF-2α in Normal Human Tissues, Cancers, and Tumor-Associated Macrophages | Q28143066 | ||
| HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption | Q28300415 | ||
| Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia | Q28586744 | ||
| Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors | Q29615445 | ||
| Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. | Q33187344 | ||
| Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. | Q36689648 | ||
| DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents | Q36702766 | ||
| Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. | Q36977587 | ||
| Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. | Q37121685 | ||
| G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models | Q37149710 | ||
| Hypoxia-inducible factor 2 regulates hepatic lipid metabolism | Q37302297 | ||
| Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan | Q37594926 | ||
| Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. | Q39921097 | ||
| Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis | Q40191484 | ||
| Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis | Q40191493 | ||
| Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway | Q40228024 | ||
| Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. | Q40380531 | ||
| Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells | Q40959364 | ||
| Pericytes limit tumor cell metastasis | Q41916240 | ||
| Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences | Q42274707 | ||
| Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. | Q43127349 | ||
| Differential activation of the rat phenylethanolamine N-methyltransferase gene by Sp1 and Egr-1. | Q46221774 | ||
| Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. | Q46365348 | ||
| Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer | Q46878046 | ||
| Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? | Q48586356 | ||
| Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. | Q50754378 | ||
| Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human p | Q52196113 | ||
| Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. | Q53494761 | ||
| P304 | page(s) | S19 | |
| P577 | publication date | 2010-12-20 | |
| P1433 | published in | Breast Cancer Research | Q2208481 |
| P1476 | title | Angiogenesis - still a worthwhile target for breast cancer therapy? | |
| P478 | volume | 12 Suppl 4 |
| Q53310498 | Cytochalasin H, an active anti-angiogenic constituent of the ethanol extract of Gleditsia sinensis thorns. |
| Q34498600 | Ethanol extract of Gleditsia sinensis thorn suppresses angiogenesis in vitro and in vivo |
| Q39396408 | Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells |
| Q26749138 | The Response of Macrophages and Neutrophils to Hypoxia in the Context of Cancer and Other Inflammatory Diseases |
Search more.